Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth

Targeting the Effector Site with IFN-  -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

(2014) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

(2008) Robbert G. van der Most et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines

(2008) Joseph D. Miller et al.   IMMUNITY

Efficient tumour formation by single human melanoma cells

(2008) Elsa Quintana et al.   NATURE

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

(2008) K. Takeda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA